Mammary Cell News 8.22 June 9, 2016 | |
| |
TOP STORYResearchers Uncover How “Silent” Genetic Changes Drive Cancer Scientists described how fluctuations in the amount of tRNAs can have a dramatic impact not only on the fate of a single cell, but also on diseases like metastatic breast cancer. [Press release from the Rockefeller University discussing online prepublication in Cell] Press Release | Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHResearchers report the development of orthotopic patient-derived xenografts of HER2-expressing breast cancer brain metastases, and their use for the identification of targeted combination therapies. [Nat Med] Abstract | Press Release The authors identified that the lysine-specific demethylase KDM3A played a dual role in breast cancer cell invasion and apoptosis by demethylating histone and the non-histone protein p53, respectively. [Oncogene] Abstract A series of novel dioxin-containing pyrazoline derivatives with thiourea skeleton have been designed, synthesized and evaluated for their EGFR/HER-2 inhibitory and anti-proliferation activities. A majority of them displayed selective HER-2 inhibitory activity against EGFR inhibitory activity. [Sci Rep] Full Article Regulation of Alternative Splicing of Bcl-X by BC200 Contributes to Breast Cancer Pathogenesis Scientists showed that BC200 is upregulated in breast cancer; among breast tumor specimens there is a higher level of BC200 in estrogen receptor (ER) positive than in ER-negative tumors. [Cell Death Dis] Full Article PPAR-Delta Promotes Survival of Breast Cancer Cells in Harsh Metabolic Conditions High PPARδ protein levels in rat breast adenocarcinomas were found to be associated with increased growth in soft agar and mice. Transgenic expression of PPARδ increased the ability of human breast cancer cell lines to migrate in vitro and form lung metastases in mice. [Oncogenesis] Full Article Dietary methionine restriction (MR) improves healthspan in part by reducing adiposity and by increasing insulin sensitivity in rodent models. Investigators determined whether MR inhibits tumor progression in breast cancer xenograft model and breast cancer cell lines. [BMC Cancer] Full Article The authors generated an in vitro mammosphere of two breast cancer cell lines, and demonstrated the mammosphere to grow and enrich cancer cells with stem-like properties, including self-renewal, multilineage differentiation and enrichment of cells expressing breast cancer stem-like cell biomarkers CD44+/CD24-/low. [Cancer Biol Ther] Abstract CLINICAL RESEARCHHERMIONE was open-label, multicenter, randomized (1:1) Phase II trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice (gemcitabine, capecitabine, or vinorelbine) plus trastuzumab planned to enroll 250 anthracycline-naïve patients with locally advanced/metastatic HER2-positive breast cancer. [BMC Cancer] Full Article | |
| |
REVIEWSBinuclear Cells in the Lactating Mammary Gland: New Insights on an Old Concept? The absolute requirement for DNA synthesis in nulliparous mouse mammary explants stimulated to synthesize milk protein in vitro has remained unexplained, as has the need for DNA synthesis prior to the onset of lactation. From a historical perspective, it is more likely that binuclear secretory cells in the lactating mammary gland are a consequence of the DNA synthesis requirement for lactation, rather than an essential element. [J Mammary Gland Biol Neoplasia] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field.
| |
SCIENCE NEWSAgendia, Inc. has presented new prospective data for its MammaPrint® 70-gene breast cancer recurrence assay. Results from the Prospective study of MammaPrint in breast cancer patients with an Intermediate recurrence Score show that MammaPrint can provide clear guidance on whether a patient should receive chemotherapy, compared to the indeterminate results from 21-gene assay. [Press release from Agendia, Inc. discussing research presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release Biotheranostics announced new independent data validating a new Breast Cancer Index (BCI) prognostic model specifically developed for ER+ breast cancer patients with 1‑3 positive lymph nodes. Data solidify BCI’s clinical utility by demonstrating the test can now predict the risk of distant recurrence from diagnosis through 15 years for early‑stage, ER+ breast cancer patients with 1‑3 positive nodes. [Press release from Biotheranostics discussing research presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release OBI Pharma, Inc. announced that Phase II/III data evaluating the clinical benefit and immunogenicity of OBI-822/OBI-821 (formerly OPT-822/OPT-821), an investigational active immunotherapy in patients with metastatic breast cancer. The study did not meet the primary efficacy end point of progression-free survival in patients with late stage metastatic breast cancer. [Press release from OBI Pharma, Inc. discussing research presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release Foundation Medicine, Inc. presented new data in two presentations that underscore the critical importance of integrating comprehensive genomic profiling into clinical care programs for the treatment of advanced breast cancer. [Press release from Foundation Medicine, Inc. discussing research presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release UPCI-Led International Trial Changing Standard of Care for Advanced Breast Cancer Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients’ lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute professor revealed. [Press release from the University of Pittsburgh discussing research presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release | |
From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.
| |
INDUSTRY NEWSTapImmune, Inc. announced that the company has exercised its option agreement with Mayo Clinic and signed a worldwide license agreement to a proprietary HER2neu vaccine technology. The license gives TapImmune the right to develop and commercialize the technology in any cancer indication in which the Her2neu antigen is overexpressed. This technology, developed in the laboratory of Keith Knutson, Ph.D. at Mayo Clinic, has completed Phase I clinical trials in HER2neu breast cancer patients. [TapImmune, Inc. (PR Newswire Association LLC.)] Press Release Atossa Genetics Initiates Additional Drug Development Program Atossa Genetics Inc. announced that it has initiated a new drug development program with oral endoxifen. Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer. [Atossa Genetics Inc.] Press Release NIH Awards Brown $11.5 Million for Computational Biology Research With a new five-year, $11.5 million grant from the National Institutes of Health, Brown University will expand its research in computational biology and launch a new Center of Biomedical Research Excellence, which will support five early career faculty members as they tackle the genomics underlying diseases such cancer, preeclampsia and severe lung infections. [Brown University] Press Release
| |
EVENTSNEW 7th International Conference on Stem Cells and Cancer (ICSCC-2016): Proliferation, Differentiation and Apoptosis Visit our events page to see a complete list of events in the mammary cell community.
| |
JOB OPPORTUNITIESNEW Publisher – Genome & BMC Biology, Genome & BCM Medicine (Springer Nature) NEW Postdoctoral Fellowship – Cancer Research (German Cancer Research Center) Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.) Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.) Postdoctoral Fellow – Proteogenomic Bioinformatics of Breast Cancer (Lund University) Postdoctoral Fellow – Mammary Gland Biology and Breast Cancer (University of Amsterdam) Clinical Scientist – Phase III Trial in HER2+ (University of Padova) Postdoctoral Fellow – Cancer Biology (Hamad bin Khalifa University) PhD Fellow – Small X-Ray Angle for Breast Cancer Diagnosis (CEA Tech) Postdoctoral Fellow(s) – Various Projects (National University of Singapore) Research Associate – Various Medical Disciplines (Jinan University) Postdoctoral Fellow – RNA Splicing in Breast Cancer (Memorial Sloan Kettering Cancer Center) Scientist – Cancer Research (Institute of Clinical Physiology) Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center) Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Mammary Cell News Volume 8.22 | Jun 9 2016